Payment overview · 2025
General Payments
$33,111.11
62 reported records · 9 companies
Healthcare provider profile · identity verified
Daniel Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1104876093
Verified facts
What the public records show
CMS Open Payments records show Daniel Lee, M.D. received $33,111.11 in general payments during 2025 across 62 reported records.
EMD Serono, Inc. accounted for 53.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cabenuva, Dovato.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Pifeltro by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $17,732.48 | 53.5% | 26 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $14,413.44 | 43.5% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $304.61 | 0.9% | 10 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $221.65 | 0.7% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $200.31 | 0.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.84 | 0.4% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $82.94 | 0.2% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.53 | 0.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.31 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,295.00 | 3 |
| Consulting Fee | $9,000.00 | 3 |
| Honoraria | $3,960.00 | 1 |
| Travel and Lodging | $2,662.14 | 10 |
| Food and Beverage | $2,193.97 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $14,413.44 | 12 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $315.85 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $200.31 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.84 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $95.99 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $95.99 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $82.94 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $82.94 | 3 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $82.94 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $82.94 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
321 | 50 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
121 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
111 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 321 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 37 |
| Gabapentin | Gabapentin | 215 | 33 |
| Lisinopril | Lisinopril | 202 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 33 |
| Omeprazole | Omeprazole | 167 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 32 |
| Testosterone | Testosterone | 160 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 22 |
| Ibuprofen | Ibuprofen | 138 | 32 |
| Bupropion Xl | Bupropion Hcl | 131 | 14 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 131 | 15 |
| Metformin Hcl | Metformin Hcl | 130 | 16 |
| Trazodone Hcl | Trazodone Hcl | 126 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 20 |
| Descovy | Emtricitabine/Tenofov Alafenam | 121 | 14 |
| Valacyclovir | Valacyclovir Hcl | 116 | 21 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 115 | 11 |
| Acyclovir | Acyclovir | 114 | 19 |
| Egrifta Sv | Tesamorelin Acetate | 113 | 15 |
| Diazepam | Diazepam | 111 | 15 |
| Dovato | Dolutegravir Sodium/Lamivudine | 111 | 15 |
| Tivicay | Dolutegravir Sodium | 109 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 17 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 104 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 19 |
| Pifeltro | Doravirine | 101 | 15 |
| Darunavir | Darunavir | 96 | 11 |
| Fluconazole | Fluconazole | 87 | 12 |
| Ozempic | Semaglutide | 80 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 78 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 74 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 73 | 15 |
| Oxycontin | Oxycodone Hcl | 69 | suppressed |
| Mirtazapine | Mirtazapine | 65 | suppressed |
| Mounjaro | Tirzepatide | 65 | 11 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 63 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | suppressed |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Lorazepam | Lorazepam | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Pregabalin | Pregabalin | 49 | suppressed |
| Serostim | Somatropin | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 44 | suppressed |
| Eszopiclone | Eszopiclone | 42 | suppressed |
| Losartan Potassium | Losartan Potassium | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 23 |
| Ketoconazole | Ketoconazole | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Furosemide | Furosemide | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Isentress | Raltegravir Potassium | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 11 |
| Finasteride | Finasteride | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 13 |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Ritonavir | Ritonavir | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Dapsone | Dapsone | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Maraviroc | Maraviroc | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Nevirapine Er | Nevirapine | 22 | suppressed |
| Etravirine | Etravirine | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Prezista | Darunavir | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Edurant | Rilpivirine Hcl | 18 | suppressed |
| Wegovy | Semaglutide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Valtrex | Valacyclovir Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitro-Bid | Nitroglycerin | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Truvada | Emtricitabine/Tenofovir (Tdf) | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33,111.11 · 62 records | EMD Serono, Inc. | APRETUDE, CABENUVA, CeQur Simplicity, DOVATO, EGRIFTA, NUPLAZID, SIMPONI, SIMPONI ARIA, STELARA, TREMFYA, TROGARZO, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cabenuva play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with EMD Serono, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error